Showing 2,657 results

Filters Content type: News, Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

Hepatitis C transmission & prevention

Men on PrEP & HIV-positive men are getting hepatitis C during sex—here’s why

Editor's pick
BETA blog
18 August 2017
Hepatitis C symptoms & diagnosis

Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV

News
17 August 2017
Hepatitis B

Gilead's hepatitis B therapy to vie with 20 Korean therapies

Editor's pick
Korea Biomedical Review
14 August 2017
Hepatitis C treatment

Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment

News
10 August 2017
Hepatitis B

UK rations hepatitis B vaccine amid global shortage

Editor's pick
BBC Health
8 August 2017
Pharmaceutical industry

AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

Editor's pick
Bloomberg
7 August 2017
New & experimental hepatitis C treatment

European and US regulators approve AbbVie's new combo for all hepatitis C genotypes

News
7 August 2017
Hepatitis C treatment

Direct-acting antivirals successfully treating hepatitis C, says Public Health England

Editor's pick
Pharmaceutical Journal
2 August 2017
Hepatitis B

Hepatitis B added to routine baby injections

Editor's pick
BBC News
1 August 2017
Hepatitis C treatment

Australia leads the world in hepatitis C treatment – what's behind its success?

Editor's pick
The Conversation AU
31 July 2017
Hepatitis C treatment

Substantial fall in Hepatitis C rates in Canberra's jail with new treatments

Editor's pick
The Canberra Times
31 July 2017
Hepatitis C treatment

Hepatitis C patients unable to get drugs due to funding problems

Editor's pick
Irish Times
31 July 2017
New & experimental hepatitis C treatment

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

Editor's pick
AbbVie press release
31 July 2017
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C

Editor's pick
Gilead press release
31 July 2017
Hepatitis C treatment

From chronic to cured: could Australia be the first country in the world to eliminate hep C?

Editor's pick
Kirby Institute
28 July 2017
Hepatitis & HIV

ECDC estimate: Around 9 million Europeans are affected by chronic hepatitis B or C

Editor's pick
Eurekalert Inf Dis
27 July 2017
New & experimental hepatitis C treatment

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

News
26 July 2017
Hepatitis C treatment

Hepatitis C treatment is effective and feasible in Africa

News
25 July 2017
New & experimental hepatitis C treatment

WHO prequalifies first generic hepatitis C medicine and first HIV self-test

Editor's pick
World Health Organization
22 July 2017
New & experimental hepatitis C treatment

US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment

News
19 July 2017
New & experimental HIV treatments

The 2017 Pipeline Report

Editor's pick
Treatment Action Group
19 July 2017
Hepatitis C symptoms & diagnosis

Targeting MSM with HIV: Treatment as Prevention in the Netherlands

Editor's pick
Healio Hepatology
18 July 2017
Hepatitis B

Liver Cancer is What Killed Jailed Chinese Dissident Lu Xiaobo

Editor's pick
Hepmag
17 July 2017
Hepatitis & HIV

Non-alcoholic fatty liver disease common in people living with HIV – metabolic disorders are key risk factors

News
12 July 2017